A meeting of the Board of Directors of Concord Drugs Limited was held on Monday, 10th August 2026, commencing at 04:00 PM and concluding at 05:00 PM.

Key Board Approvals

The Board considered and approved the following:

1. The Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter ended 30th June, 2026.

2. Took note of the Limited Review Report issued by the Statutory Auditors, Pundarikashyam and Associates, on the aforesaid financial results.

Standalone Financial Results (₹ in Lakhs)

Profit & Loss Statement:

  • Revenue from Operations: ₹2,088.68 (Q1 FY27) vs. ₹1,338.35 (Q1 FY26)
  • Net sales from Operations: ₹2,088.86
  • Other Operating Income: ₹0.82
  • Total Revenue (I+II): ₹2,089.68
  • Total Expenses: ₹1,935.42
  • Cost of Material Consumed: ₹1,653.49
  • Changes in Inventories: ₹38.98
  • Employees Benefit Expenses: ₹124.57
  • Finance Costs: ₹35.11
  • Depreciation and Amortisation: ₹34.76
  • Other expenses: ₹48.52
  • Profit before tax: ₹154.26 (Q1 FY27) vs. ₹15.20 (Q1 FY26)
  • Tax Expense: ₹43.04
  • Current tax: ₹44.11
  • Deferred tax credit: ₹(1.08)
  • Profit for the period: ₹111.23 (Q1 FY27) vs. ₹11.14 (Q1 FY26)

Balance Sheet & Ratios:

  • Paid-up Capital: ₹1,317.50 (Face value ₹10 per share)
  • Other Equity: ₹3,645.12
  • Earnings Per Share (EPS) (Basic): ₹0.84 (Q1 FY27) vs. ₹0.11 (Q1 FY26)
  • Earnings Per Share (EPS) (Diluted): ₹0.84 (Q1 FY27) vs. ₹0.11 (Q1 FY26)

Consolidated Financial Results (₹ in Lakhs)

Profit & Loss Statement:

  • Total Revenue: ₹2,094.70
  • Total Expenses: ₹1,940.21
  • Profit before tax: ₹154.49
  • Tax Expense: ₹43.10
  • Current tax: ₹44.15
  • Deferred tax credit: ₹(1.06)
  • Profit for the period: ₹111.40
  • Earnings Per Share (EPS) (Basic): ₹0.85

Subsidiary Information:

The consolidated results include the unaudited interim financial results of one subsidiary, Proton Remedies Private Limited, which contributed total revenues of ₹36.54 lakhs and a net profit after tax of ₹0.23 lakhs for the quarter.

Notes to the Financial Results

1. The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS).

2. The results were reviewed by the audit committee and approved by the Board of Directors.

3. Figures for previous periods have been regrouped and reclassified for comparability.

4. The EPS for the quarter is not strictly comparable on a QoQ and YoY basis due to an increase in the weighted average number of equity shares. This increase of over 33% in share capital resulted from the allotment of 31,75,000 equity shares at ₹36.50 per share through a preferential issue.

5. Despite this dilution, the EPS improved, reflecting that profitability growth outpaced the increase in the equity share base.

Disclosure & Availability

The financial results were published pursuant to Regulation 30 and Regulation 33 of the SEBI (LODR) Regulations, 2015. They are available on the company's website (www.concorddrugs.in) and the website of BSE Limited. The results will also be published in newspapers as required.

Auditor's Review Report

The statutory auditors, Pundarikashyam and Associates, issued a limited review report stating that based on their review, nothing has come to their attention that causes them to believe that the Statement contains any material misstatement and has been prepared in accordance with Ind AS 34, the SEBI Circular, and other accounting principles generally accepted in India. This conclusion extends to the consolidated results, relying on the review reports of the subsidiary's auditors.